Policy

MIT researchers have built “the first complete model of pedestrian activity in New York City,” a template that could be applied to any U.S. city, reports Elissaveta M. Brandon for Fast Company. “The model, which maps foot traffic across all sidewalks, crosswalks and footpaths in NYC during peak periods, reveals surprising patterns about the way people move around the city, as well as where they are most vulnerable to vehicle crashes,” explains Brandon. “It could have tremendous benefits for city planners.” 

Prof. Jim Walsh speaks with WBUR’s Here & Now host Tiziana Dearing about increased military presence in the Middle East and methods to de-escalate tensions. 

Lecturer Jim Aloisi speaks with Boston Globe reporter Ian Prasad Philbrick about fare evasion on the MBTA, and a need for transit reform. “The drill here shouldn’t be to obsess or focus about how much,” says Aloisi. “The drill should be where can we make cost-effective interventions that matter?”

Prof. Jim Walsh speaks with Fox News reporter Jon Scott about international relations between the United States and countries in the Middle East. 

Prof. Jim Walsh speaks with WBUR’s Here and Now host Scott Tong about U.S. global negotiations and relationships. 

Prof. Christopher Palmer speaks with WBUR On Point host Meghna Chakrabarti about Americans and credit card debt, and how an interest rate cap could affect households across the country. “Anytime you have a price control, it has unintended consequences,” says Palmer. “Sometimes they're subtle. In this case, they're not subtle to see. We have lots of countries, lots of places where we've studied the effect of a cap on interest rates, and we see all sorts of unintended consequences.” 

Prof. Jonathan Gruber speaks with David Frum from The Atlantic’s “The David Frum Show” to shed light on the American healthcare system and health care disparities. “The issue in the U.S. is there are the haves and the have-nots—the haves get comparable health care to the rest of the world at a much higher price; the have-nots get worse health care at a much higher price,” says Gruber. “There’s really two fundamental challenges in U.S. health care: There’s disparities, and there’s costs.” 

Prof. Jonathan Gruber speaks with Boston 25 reporter Amal Elhewl about the anticipated rise in healthcare premiums. Gruber predicts “prices could jump by as much as $25,000 a year for people like small business owners or entrepreneurs,” Elhewl explains. “If 4 to 5 million people lose health insurance, we’re talking about on the order of 5,000 extra deaths every year because we have not extended these subsidies,” adds Gruber. 

Writing for the Financial Times, Principal Research Scientist Florian Berg explores “reasons to be hopeful about the resilience of efforts to tackle environmental issues at the corporate level.” Berg explains: “When looking at reporting on carbon emissions, ESG data and money invested in sustainable investment strategies, we can see big increases in recent years.” 

Prof. Jonathan Gruber speaks with Newsweek reporter Jasmine Laws about the rise of health insurance premiums in the United States. “States with very active management and lots of competition on the exchanges will see the lowest increases,” says Gruber. 

Prof. Pierre Azoulay speaks with WBUR’s Martha Bebinger about a new study examining the potential impact of NIH budget cuts on the development of new medicines. Azoulay and his colleagues found that “more than half of drugs approved by the FDA since 2000 used NIH-funded research that would likely not have happened if the NIH had operated with a 40% smaller budget,” Bebinger explains. 

Fierce Biotech reporter Darren Incorvaia writes that a new study by MIT researchers demonstrates how potential NIH budget cuts could endanger the development of new medications. The researchers found that if the NIH budget had been 40% smaller from 1980 to 2007, the level of NIH cuts currently being proposed, “the science underlying numerous drugs approved in the 21st century would not have been funded,” Incorvaia explains. The findings suggest that “massive cuts of the kind that are being contemplated right now could endanger the intellectual foundations of the drugs of tomorrow,” explains Professor Pierre Azoulay. 

A new study co-authored by MIT researchers finds that more than half of the drugs approved by the FDA since 2000 are connected to NIH research that would be impacted by proposed 40 percent budget cuts, reports Genetic Engineering & Biotechnology News. 

Institute Prof. Daron Acemoglu participated in a “global dialogue on artificial intelligence governance” at the United Nations, reports Steve Lohr for The New York Times. “The AI quest is currently focused on automating a lot of things, sidelining and displacing workers,” says Acemoglu. 

In an opinion piece for the Financial Times, Prof. Evan Lieberman, director of the MIT Center for International Studies, spotlights how states, cities, corporations, and civil society are working to advance climate action. “Today, over 300 U.S. cities have made climate commitments, action plans, or are participating in co-operative initiatives,” Lieberman writes, “Large cities are connecting with global partners through organizations such as C40 Cities, a group of mayors representing some 700mn people worldwide.”